When dividing the COVID-19 group according to the insulin regimen therapy, at Time 2 we found a corresponding significant increase in GMI (P < 0.001), mean glucose (P < 0.001), SD (P = 0.001), and TAR level 2 (P = 0.003) associated with a reduction of TBR level 2 in patients treated with MDI (N = 15) but not in those using CSII (N = 17) (Table 3). Here, INS is linked to COVID-19.